The global intragastric balloons market is entering a strong growth phase as obesity rates rise and patients increasingly seek effective, minimally invasive alternatives to conventional bariatric surgery. The market was valued at USD 86.8 million in 2025 and is projected to reach USD 364.6 million by 2036, expanding at a CAGR of 13.9% from 2026 to 2036.

👉 Get sample market research report copy now@ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=26006

An intragastric balloon is a temporary medical device placed inside the stomach to occupy space and promote earlier satiety, helping patients reduce food intake and achieve weight loss. Traditional systems are generally inserted endoscopically through the mouth and esophagus, avoiding surgical incisions. Growing awareness of non-surgical obesity management, improved clinical outcomes, and technological innovation are creating new opportunities for hospitals, specialty clinics, and obesity-management providers.

Market Overview

The intragastric balloons market is being shaped by increasing obesity prevalence, greater awareness of endoscopic weight-loss procedures, and advances in balloon design. The market reached USD 86.8 million in 2025 and is expected to more than quadruple to USD 364.6 million by 2036.

North America dominated the market in 2025 with a revenue share of approximately 41.2%, supported by high obesity prevalence, established healthcare infrastructure, specialized bariatric centers, and growing acceptance of minimally invasive procedures. By product type, the single balloon segment held the largest share at 54.2% in 2025, reflecting its established clinical use, simpler placement, and broad availability.

Major companies include Boston Scientific Corporation, Apollo Endosurgery, Medtimo, Spatz FGIA, GI Alliance, Medispar, Helioscopie, Laboratoire Endalis, Silimed, MICRO-TECH, Bariatric Solutions, and OxiGênios.

Key Drivers of Market Growth

Rising Global Prevalence of Obesity and Overweight
The increasing prevalence of obesity and overweight populations worldwide is a primary growth driver. Sedentary lifestyles, urbanization, changing dietary patterns, and increased consumption of calorie-dense processed foods have contributed to the expanding obesity burden.

Obesity is closely associated with chronic conditions including type 2 diabetes, cardiovascular disease, hypertension, sleep apnea, and certain cancers. Consequently, patients and healthcare providers are seeking weight-management options that can deliver meaningful results without the risks and recovery requirements associated with major surgery.

Intragastric balloons provide a temporary approach that can create a feeling of fullness while supporting reduced food intake. Rising awareness of endoscopic obesity treatments, increasing healthcare expenditure, and expanding bariatric infrastructure are expected to sustain demand.

Technological Advancements in Swallowable and Adjustable Systems
Innovation is becoming a major competitive factor. Swallowable balloon technologies can reduce or eliminate the need for conventional endoscopic placement and anesthesia in suitable patients, potentially improving accessibility and convenience.

Adjustable balloon systems provide physicians with greater flexibility by allowing balloon volume to be modified according to patient tolerance and treatment response. Improvements in materials, valve systems, durability, and balloon design are also aimed at reducing complications such as deflation, migration, discomfort, and difficult removal.

Increasing clinical evidence, regulatory approvals, product launches, and research investment are supporting commercialization. These developments could broaden the addressable patient population and strengthen the role of balloon therapy within comprehensive obesity-management programs.

Key Players and Industry Leaders

The competitive landscape includes established medical-device companies and specialized obesity-treatment innovators. Key players include Boston Scientific Corporation, Apollo Endosurgery, Medtimo, Spatz FGIA, GI Alliance, Medispar, Helioscopie, Laboratoire Endalis, Silimed, MICRO-TECH (Nanjing) Co., Ltd., Bariatric Solutions GmbH, and OxiGênios.

Companies are focusing on product innovation, regulatory approvals, clinical evidence, geographic expansion, and partnerships with healthcare providers. In February 2026, Allurion Technologies announced FDA approval for its Allurion Gastric Balloon System featuring the Allurion Smart Capsule, designed to be swallowed during an office visit and placed without surgery, endoscopy, or anesthesia.

Explore our report to uncover in-depth insights - https://www.transparencymarketresearch.com/intragastric-balloons-market.html

Market Segmentation

By Product Type: Single Balloon, Dual Balloon, Triple Balloon

By Filling Material: Saline-Filled Balloons, Gas-Filled Balloons

By Duration of Implantation: Up to 6 Months, 6-12 Months, More than 12 Months

By Patient Type: Adults, Adolescents

By End User: Hospitals, Ambulatory Surgical Centers (ASCs), Specialty Clinics, Others

By Region: North America, Europe, Asia Pacific, Latin America, Middle East & Africa

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Media Contact:

Abhishek Budholiya
Transparency Market Research Inc.
State Tower, 90 State Street, Suite 700,
Albany NY - 12207, United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453